Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients

European Journal of Cancer

Volumn 49, Issue 8, 2013, Pages 1898-1904

  Levy, Antonin ^a   Menard, Jean ^a   Albiges, Laurence ^a   Loriot, Yohann ^a   Di Palma, Mario ^a   Fizazi, Karim ^a   Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Metastatic renal cell carcinoma; Second line; Targeted therapy

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ASTHENIA; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; KIDNEY METASTASIS; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTENSION; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; SIROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876685070     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.02.003     Document Type: Article

References (19)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. B. Escudier, V. Kataja ESMO Guidelines Working Group Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20S4 2009 81 82
3. R.J. Motzer, N.H. Bander, and D.M. Nanus Renal-cell carcinoma N Engl J Med 335 1996 865 875
4. V.T. DeVita Jr., S. Hellman, and S.A. Rosenberg Cancer: principles and practice of oncology 6th ed. 2001 Lippincott Williams & Wilkins Philadelphia, PA, USA
5. R.J. Motzer, J. Bacik, B.A. Murphy, P. Russo, and M. Mazumdar Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296
6. B. Escudier, J. Bellmunt, and S. Négrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
7. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
8. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
9. B.I. Rini, B. Escudier, and B. Tomczak Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma: results of phase III AXIS trial (abstract #4503) J Clin Oncol 29 2011 289s
10. R.J. Motzer, B. Escudier, and S. Oudard RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
11. M.P. Sablin, S. Negrier, and A. Ravaud Sequential sorafenib and sunitinib for renal cell carcinoma J Urol 182 2009 29 34
12. A.Z. Dudek, J. Zolnierek, and A. Dham Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 2009 61 67
13. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
14. R.J. Motzer, J. Bacik, and L.H. Schwartz Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 2004 454 463
15. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
16. M.M. Vickers, T.K. Choueiri, and M. Rogers Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy Urology 76 2010 430 434
17. R.J. Motzer, J. Bacik, and M. Mazumdar Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience Clin Cancer Res 10 2004 6302S
18. Porta C, Szczylik C, Escudier B. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. Crit Rev Oncol Hematol; 2011 [Epub ahead of print].
19. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794